PRESS RELEASES
Royal Wound-X Receives IRB Approval and Commences Randomized Controlled Trials for Pivotal Products
September 11, 2024
Royal Biologics Announces Licensing and U.S. Commercial Launch of Bio-Reign 3D (TM)
May 23, 2023
Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM
February 14, 2023
Royal Biologics Announces U.S. Commercial Launch of Advanced-Cell™, an Advanced Bone Grafting and Fusion Convenience Kit
April 26, 2022
Royal Biologics Announces Partnership With Vilex Launching Its ALC Technology Into Lower Extremity Industry
August 17, 2021
Royal Biologics Wound Care Portfolio Receives High-Tier Reimbursement
February 15, 2021
Royal Biologics Announces the Launch of Fibri-Cell™, Live Cellular Cortical Fibers With Osteo-Spin™ Technology
November 10, 2020
Royal Biologics Completes 100th Cyro Cord™ Case, Successfully Enrolls First Patient Into Diabetic Foot Ulcer Study
September 29, 2020
Royal Biologics Announces the Acquisition of FIBRINET
September 1, 2020
Royal Biologics Announces the Launch of Cryo-Cord™, the First Non-DMSO Viable Umbilical Cord Graft
January 21, 2020
Royal Biologics announces the launch of MAGNUS, a DMSO-free viable cellular bone allograft
January 8, 2020
Granite Creek Capital Partners, L.L.C. Announces an Investment in Royal Biologics
January 19, 2019
Royal Biologics Launches Maxx-Cell, the World’s Most Advanced Bone Marrow Aspiration Device
December 12, 2018
Royal Biologics Launches MAXX™-Fuse
Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue